Merck's ADC sac‑TMT gets its first global Phase 3 win ahead of schedule on May 19, 2026 Co. global trial Malignant neoplasm of endometrium Merck Multiple Sulfatase Deficiency Disease Overall Survival Pharmacotherapy Phase 3 sacituzumab tirumotecan therapeutic autologous dendritic cells TROP2 +